Leslie Wai Louie

US Patent:

6749868, Jun 15, 2004

Filed:

May 21, 1999

Appl. No.:

09/316642

Inventors:

Neil P. Desai - Los Angeles CA
Chunlin Tao - Beverly Hills CA
Andrew Yang - Rosemead CA
Leslie Louie - Montebello CA
Zhiwen Yao - Culver City CA
Patrick Soon-Shiong - Los Angeles CA
Shlomo Magdassi - Jerusalem, IL

Assignee:

American BioScience, Inc. - Santa Monica CA

International Classification:

A61K 916

US Classification:

424491, 424489, 424490

Abstract:

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e. g. , addition of a polar solvent to the organic phase), and careful election of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound.

US Patent:

20120231082, Sep 13, 2012

Filed:

Feb 7, 2012

Appl. No.:

13/368297

Inventors:

Neil P. DESAI - Los Angeles CA, US
Chunlin Tao - Los Angeles CA, US
Andrew Yang - Rosemead CA, US
Leslie Louie - Montebello CA, US
Patrick Soon-Shiong - Los Angeles CA, US

International Classification:

A61K 31/337
A61P 35/00
A61K 9/14
B82Y 5/00

US Classification:

424491, 514449, 424400, 977773, 977788, 977915

Abstract:

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

US Patent:

59165960, Jun 29, 1999

Filed:

Oct 1, 1996

Appl. No.:

8/720756

Inventors:

Neil P. Desai - Los Angeles CA
Chunlin Tao - Beverly Hills CA
Andrew Yang - Rosemead CA
Leslie Louie - Montebello CA
Tianli Zheng - Culver City CA
Zhiwen Yao - Culver City CA
Patrick Soon-Shiong - Los Angeles CA
Shlomo Magdassi - Jerusalem, IL

Assignee:

Vivorx Pharmaceuticals, Inc. - Santa Monica CA

International Classification:

A61K 914

US Classification:

424489

Abstract:

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e. g. , addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered.

US Patent:

20150111960, Apr 23, 2015

Filed:

Oct 2, 2014

Appl. No.:

14/505452

Inventors:

- Los Angeles CA, US
Chunlin TAO - Los Angeles CA, US
Andrew YANG - Rosemead CA, US
Leslie LOUIE - Montebello CA, US
Patrick SOON-SHIONG - Los Angeles CA, US

International Classification:

A61K 31/337
A61K 47/42
A61K 9/107

US Classification:

514449

Abstract:

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.